Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Short Interest Update

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) was the target of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 36,400 shares, a decrease of 24.6% from the August 31st total of 48,300 shares. Based on an average trading volume of 133,400 shares, the days-to-cover ratio is presently 0.3 days. Approximately 2.8% of the shares of the company are sold short.

Pieris Pharmaceuticals Stock Performance

Pieris Pharmaceuticals stock traded up $0.43 during trading hours on Friday, reaching $16.59. 5,203 shares of the stock were exchanged, compared to its average volume of 52,779. The stock has a market cap of $21.90 million, a P/E ratio of -1.36 and a beta of 0.66. The firm’s 50 day moving average is $16.41 and its 200 day moving average is $13.09. Pieris Pharmaceuticals has a 52-week low of $6.20 and a 52-week high of $26.80.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($2.76) earnings per share (EPS) for the quarter. Pieris Pharmaceuticals had a negative return on equity of 101.29% and a negative net margin of 39.71%.

Analyst Ratings Changes

Separately, StockNews.com lowered Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 16th.

Insider Transactions at Pieris Pharmaceuticals

In other Pieris Pharmaceuticals news, major shareholder Adar1 Capital Management, Llc acquired 3,000 shares of the stock in a transaction on Friday, August 9th. The shares were bought at an average cost of $14.89 per share, with a total value of $44,670.00. Following the transaction, the insider now owns 127,331 shares of the company’s stock, valued at approximately $1,895,958.59. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 8.89% of the company’s stock.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.